01

Diclofenac

Brand: Cambia · 9.4M Part D claims (CY24) · 3.8M beneficiaries · First FDA approval: 1996-03-26

41 generic mfrs 275 plans require PA

Low NADAC$0.069

→

Avg plan cost$2.11

Part D spend $610.4M 30× spread, current vs floor

Class share

48%

of class CY24 spend

View profile →

02

Celecoxib

Brand: CELEBREX · 8.8M Part D claims (CY24) · 3.3M beneficiaries · First FDA approval: 1998-10-02

18 generic mfrs 1 plans require PA Discontinued

Low NADAC$0.071

→

Avg plan cost$1.04

Part D spend $257.9M 15× spread, current vs floor

Class share

20%

of class CY24 spend

View profile →

03

Bromfenac

Brand: BROMSITE · 378K Part D claims (CY24) · 214K beneficiaries · First FDA approval: 2013-04-05

7 generic mfrs 0 plans require PA

Low NADAC$12.14

→

Avg plan cost$27.12

Part D spend $90.4M 2× spread, current vs floor

Class share

7%

of class CY24 spend

View profile →

04

Meloxicam

Brand: QAMZOVA · 18.2M Part D claims (CY24) · 7.0M beneficiaries · First FDA approval: 2005-11-01

13 generic mfrs 0 plans require PA

Low NADAC$0.016

→

Avg plan cost$0.962

Part D spend $82.8M 59× spread, current vs floor

Class share

7%

of class CY24 spend

View profile →

05

Ibuprofen

Brand: Caldolor · 11.4M Part D claims (CY24) · 6.2M beneficiaries · First FDA approval: 2001-11-14

13 generic mfrs 0 plans require PA

Low NADAC$0.024

→

Avg plan cost$0.045

Part D spend $75.6M 2× spread, current vs floor

Class share

6%

of class CY24 spend

View profile →

06

Naproxen

Brand: EC-NAPROXEN · 4.4M Part D claims (CY24) · 2.2M beneficiaries · First FDA approval: 2007-04-26

17 generic mfrs 0 plans require PA

Low NADAC$0.046

→

Avg plan cost$0.648

Part D spend $57.0M 14× spread, current vs floor

Class share

5%

of class CY24 spend

View profile →

07

Nepafenac

Brand: ILEVRO · 55K Part D claims (CY24) · 31K beneficiaries · First FDA approval: 2024-05-01

Brand-only (no generics) 0 plans require PA

Low NADAC$105.00

→

Avg plan cost$113.09

Part D spend $22.4M 1× spread, current vs floor

Class share

2%

of class CY24 spend

View profile →

08

Nabumetone

Brand: RELAFEN DS · 865K Part D claims (CY24) · 353K beneficiaries · First FDA approval: 2002-02-25

8 generic mfrs 0 plans require PA

Low NADAC$0.128

→

Avg plan cost$2.40

Part D spend $20.7M 19× spread, current vs floor

Class share

2%

of class CY24 spend

View profile →

09

Etodolac

391K Part D claims (CY24) · 170K beneficiaries · First FDA approval: 1998-03-11

11 generic mfrs 0 plans require PA

Low NADAC$0.253

→

Avg plan cost$0.660

Part D spend $15.9M 3× spread, current vs floor

Class share

1%

of class CY24 spend

View profile →

10

Diflunisal

Brand: Dolobid · 16K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2012-03-08

3 generic mfrs 0 plans require PA

Low NADAC$1.19

→

Avg plan cost$1.19

Part D spend $8.0M 1× spread, current vs floor

Class share

1%

of class CY24 spend

View profile →

11

Indomethacin

Brand: INDOCIN · 400K Part D claims (CY24) · 216K beneficiaries · First FDA approval: 1984-08-06

16 generic mfrs 82 plans require PA

Low NADAC$0.096

→

Avg plan cost$0.152

Part D spend $6.9M 2× spread, current vs floor

Class share

1%

of class CY24 spend

View profile →

12

Piroxicam

76K Part D claims (CY24) · 29K beneficiaries · First FDA approval: 1994-01-26

6 generic mfrs 0 plans require PA

Low NADAC$0.153

→

Avg plan cost$0.170

Part D spend $6.7M 1× spread, current vs floor

Class share

1%

of class CY24 spend

View profile →

13

Sulindac

227K Part D claims (CY24) · 90K beneficiaries · First FDA approval: 1990-04-03

3 generic mfrs 0 plans require PA

Low NADAC$0.189

→

Avg plan cost$0.208

Part D spend $4.4M 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

14

Ketoprofen

Brand: Orudis · 4K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2003-09-04

3 generic mfrs 0 plans require PA

Low NADAC$6.46

→

Avg plan cost$6.46

Part D spend $3.1M 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

15

Flurbiprofen

Brand: LURBIRO · 47K Part D claims (CY24) · 24K beneficiaries · First FDA approval: 1995-01-04

2 generic mfrs 0 plans require PA

Low NADAC$3.23

→

Avg plan cost$5.55

Part D spend $2.0M 2× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

16

Oxaprozin

Brand: COXANTO · 23K Part D claims (CY24) · 8K beneficiaries · First FDA approval: 1992-10-29

4 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.595

→

Avg plan cost$0.595

Part D spend $1.7M 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

17

Mefenamic Acid

482 Part D claims (CY24) · 292 beneficiaries · First FDA approval: 2010-11-19

3 generic mfrs 0 plans require PA

Low NADAC$0.987

→

Avg plan cost$0.987

Part D spend $111440 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

18

Acetaminophen and Ibuprofen

Brand: Combogesic · — Part D claims (CY24) · First FDA approval: 2025-01-06

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

19

Acetaminophen and Ibuprofen Injection

Brand: COMBOGESIC IV · — Part D claims (CY24) · First FDA approval: 2024-02-05

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

20

Aspirin and Dipyridamole

— Part D claims (CY24) · First FDA approval: 2018-10-10

8 generic mfrs

Low NADAC$0.556

→

Avg plan cost$0.556

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

21

Aspirin and Extended - Release Dipyridamole

— Part D claims (CY24) · First FDA approval: 2017-01-30

Brand-only (no generics)

Low NADAC$0.556

→

Avg plan cost$0.556

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

22

Asprin and Extended-Release Dipyridamole

— Part D claims (CY24) · First FDA approval: 2019-05-24

Brand-only (no generics) 0 plans require PA

Low NADAC$0.556

→

Avg plan cost$0.556

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

23

Butalbital, Aspirin, Cafeine, and Codeine

Brand: Ascomp with Codeine · — Part D claims (CY24) · First FDA approval: 2001-11-30

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

24

Butalbital, Aspirin, Caffeine and Codeine

Brand: Ascomp with Codeine · — Part D claims (CY24) · First FDA approval: 2009-05-01

2 generic mfrs 22 plans require PA

Low NADAC$1.06

→

Avg plan cost$1.06

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

25

Butalbital, Aspirin, and Caffeine

— Part D claims (CY24) · First FDA approval: 1985-10-11

Brand-only (no generics)

Low NADAC$0.979

→

Avg plan cost$0.979

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

26

Hydrocodone Bitartrate and Ibuprofen

— Part D claims (CY24) · First FDA approval: 2010-02-18

3 generic mfrs 0 plans require PA

Low NADAC$0.488

→

Avg plan cost$1.75

Part D spend — 4× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

27

Ibu

— Part D claims (CY24) · First FDA approval: 2008-11-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

28

Ibuorofen

Brand: IBUPROFEN · — Part D claims (CY24) · First FDA approval: 2019-08-22

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

29

Ibuprofen Oral

Brand: Ibuprofen · — Part D claims (CY24) · First FDA approval: 2018-02-16

Brand-only (no generics)

Low NADAC$0.024

→

Avg plan cost$0.032

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

30

Meloxicam, Rizatriptan

Brand: SYMBRAVO · — Part D claims (CY24) · First FDA approval: 2025-05-19

Brand-only (no generics)

Low NADAC$122.76

→

Avg plan cost$122.76

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

31

Naproxen Oral

— Part D claims (CY24) · First FDA approval: 2021-03-12

Brand-only (no generics) 6 plans require PA

Low NADAC$0.165

→

Avg plan cost$0.165

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

32

Naproxen and Esomeprazole

— Part D claims (CY24) · First FDA approval: 2020-02-18

Brand-only (no generics) 2 plans require PA

Low NADAC$2.49

→

Avg plan cost$2.53

Part D spend — 1× spread, current vs floor

Class share

0%

of class CY24 spend

View profile →

33

Orphenadrine Citrate, Aspirin and Caffeine

Brand: Norgesic · — Part D claims (CY24) · First FDA approval: 2019-04-01

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

34

Oxycodone and Aspirin

— Part D claims (CY24) · First FDA approval: 2020-06-30

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

35

Phenylephrine and Ketorolac

Brand: Omidria · — Part D claims (CY24) · First FDA approval: 2023-07-01

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

Nonsteroidal Anti-inflammatory Drug

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.